[Paper Review] Two-stage differences in differences
Introduces a two-stage estimator for staggered adoption with heterogeneous treatment effects, showing robustness where standard DiD misidentifies the average treatment effect.
A recent literature has shown that when adoption of a treatment is staggered and average treatment effects vary across groups and over time, difference-in-differences regression does not identify an easily interpretable measure of the typical effect of the treatment. In this paper, I extend this literature in two ways. First, I provide some simple underlying intuition for why difference-in-differences regression does not identify a group$ imes$period average treatment effect. Second, I propose an alternative two-stage estimation framework, motivated by this intuition. In this framework, group and period effects are identified in a first stage from the sample of untreated observations, and average treatment effects are identified in a second stage by comparing treated and untreated outcomes, after removing these group and period effects. The two-stage approach is robust to treatment-effect heterogeneity under staggered adoption, and can be used to identify a host of different average treatment effect measures. It is also simple, intuitive, and easy to implement. I establish the theoretical properties of the two-stage approach and demonstrate its effectiveness and applicability using Monte-Carlo evidence and an example from the literature.
Motivation & Objective
- Clarify why standard difference-in-differences may not identify a simple group×period average treatment effect under staggered adoption and heterogeneity.
- Propose a two-stage estimation framework that isolates group and period effects from untreated observations and then estimates the average treatment effect on the treated.
- Establish theoretical properties, including consistency and unbiasedness, and provide guidance for inference and implementation.
- Demonstrate performance via Monte Carlo simulations and an empirical application.
- Discuss extensions to event-study analyses and alternative estimands.
Proposed method
- First stage: regress outcomes on group and period fixed effects using only untreated observations to estimate λ_g and γ_p.
- Second stage: regress Y_gpit − ŀ_g − ŷ_p on D_gp to identify E(β_gp | D_gp = 1) under parallel trends.
- Interpretation: the two-stage estimator recovers the overall average treatment effect on the treated even with heterogeneity across groups and periods.
- The method can be extended to different estimands (e.g., four-period average, duration-specific effects) and to event-study settings.
- Inference can be conducted via GMM, with standard errors adjusted for generated regressors.
Experimental results
Research questions
- RQ1What does the standard DiD estimand identify when treatment effects are heterogeneous and adoption is staggered?
- RQ2Can a simple two-stage approach yield a robust, interpretable estimate of the average treatment effect on the treated under staggered adoption?
- RQ3How does the two-stage estimator perform relative to other approaches (e.g., separate group×period estimates, stacked DiD) in simulations and empirical data?
- RQ4How can the framework be extended to event studies and alternative summary measures of treatment effects?
Key findings
- Standard DiD regression does not generally identify a simple group×period average treatment effect under staggered adoption with heterogeneous effects.
- The proposed two-stage estimator identifies E(β_gp|D_gp = 1), the average treatment effect across groups and periods among the treated.
- In simulations, the two-stage estimator matches aggregated true averages and outperforms naive DiD in the presence of heterogeneity.
- In event-study contexts, the two-stage approach can recover pre-trends and the evolution of effects over the duration of treatment.
- An empirical application reproduces baseline results while illustrating how DiD weights can distort interpretation under heterogeneity.
Better researchstarts right now
From reading papers to final review, dramatically reduce your research time.
No credit card · Free plan available
This review was created by AI and reviewed by human editors.